On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's Spravato (Esketamine) nasal spray as a "monotherapy" treatment for major depressive disorder.
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major depressive disorder. The drug was first approved for in 2019 but patients also to be taking an antidepressant at the same time. Now, esketamine can be used alone. Esketamine is J&J's patented version of ketamine, a dissociative anesthetic with psychedelic properties that was first synthesized in 1962. Numerous scientific studies have demonstrated…